Cholesterol Self-testing in Patients Post Acute Coronary Syndrome

The pharmacological reduction of LDL-C lowers cardiovascular risk and is therefore a priority in cardiovascular secondary prevention. The achievement of LDL-C target levels in Germany, Europe, and worldwide is inadequate, despite a wide array of lipid-lowering medications. Only a small proportion of post-myocardial infarction patients reach their LDL-C target range within a year. There is a significant need for new strategies to improve LDL-C target achievement and thereby reduce the occurrence of secondary cardiovascular events. The aim of the study is to establish a basis for improving prevention by achieving the target LDL level effectively and quickly in patients with high and very high cardiovascular risk profiles.

NCT Number	NCT06526013
Lead Sponsor	University of Leipzig
Conditions	Acute Coronary Syndrome, Prevention, LDL Hyperlipoproteinemia, Therapeutic Adherence
Enrollment	200 participants
Start Date	2024-06-01
Primary Completion	2025-06-01 (estimated)
Study Completion	2025-09-30 (estimated)
Updated on ClinicalTrials.gov	2024-08-01